Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

被引：0
|
作者：
Li, Nanxin [1 ]
Wilson, Koo [2 ]
Botteman, Marc [3 ]
Nicoloso, Daniel [3 ]
Krishnan, Sangeeta [1 ]
Su, Jun [1 ]
机构：
[1] Bioverativ, Waltham, MA USA
[2] Swedish Orphan Biovitrum SOBI, Stockholm, Sweden
[3] Pharmerit Int, Bathesda, MD USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-114993
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3520
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein
    Groomes, Charles L.
    Gianferante, David M.
    Crouch, Gary D.
    Parekh, Dina S.
    Scott, David W.
    Lieuw, Kenneth
    PEDIATRIC BLOOD & CANCER, 2016, 63 (05) : 922 - 924
  • [2] Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
    Krishnamoorthy, Sriram
    Liu, Tongyao
    Drager, Douglas
    Patarroyo-White, Susannah
    Chhabra, Ekta Seth
    Peters, Robert
    Josephson, Neil
    Lillicrap, David
    Blumberg, Richard S.
    Pierce, Glenn F.
    Jiang, Haiyan
    CELLULAR IMMUNOLOGY, 2016, 301 : 30 - 39
  • [3] Real-world data of immune tolerance induction (ITI) using recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with severe hemophilia A with inhibitors at high risk for ITI failure
    Carcao, M.
    Shapiro, A.
    Hwang, N.
    Pipe, S.
    Ahuja, S.
    Lieuw, K.
    Staber, J.
    Belletrutti, M.
    Sun, H.
    Ding, H.
    Wang, M.
    Price, V.
    Steele, M.
    Tsao, E.
    Feng, J.
    Al-Khateeb, Z.
    Dumont, J.
    Jain, N.
    HAEMOPHILIA, 2019, 25 : 15 - 16
  • [4] Evaluation of the toxicology and pharmacokinetics of recombinant factor VIII Fc (rFVIIIFc) fusion protein in animals
    Dumont, Jennifer A.
    Loveday, Ken
    Light, David R.
    Pierce, Glenn F.
    Jiang, Haiyan
    HAEMOPHILIA, 2014, 20 : 21 - 21
  • [5] ECONOMIC EVALUATION OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) FOR IMMUNE TOLERANCE INDUCTION (ITI) IN PATIENTS WITH HEMOPHILIA A WHO DEVELOP INHIBITORS UNDER THE BRAZILIAN UNIFIED HEALTH SYSTEM (SUS) PERSPECTIVE
    Teich, V
    Li, N.
    Brito, K.
    Krishnan, S.
    Su, J.
    VALUE IN HEALTH, 2018, 21 : S251 - S251
  • [6] PERIOPERATIVE MANAGEMENT OF PATIENTS WITH SEVERE HAEMOPHILIA A WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC)
    Bocchinfuso, S.
    O'Donovan, M.
    Singleton, E.
    Benson, J.
    Byrne, M.
    Ryan, K.
    O'Donnell, J. S.
    O'Connell, N. M.
    HAEMOPHILIA, 2021, 27 : 105 - 106
  • [7] VWF affects the clearance and biodistribution of recombinant factor VIII Fc fusion (rFVIIIFc)
    Van Der Flier, A.
    Tan, S.
    Liu, Z.
    Chen, K.
    Liu, T.
    Patarroyo-White, S.
    Light, D.
    Jiang, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 476 - 476
  • [8] Recombinant factor VIII Fc (rFVIIIFc) in real life: Clinical and economic outcomes
    Delmotte, N.
    Roche, M.
    Giraud, R.
    Roche, M.
    Falaise, C.
    Chambost, H.
    Gensollen, S.
    HAEMOPHILIA, 2019, 25 : 102 - 102
  • [9] COMPARISONS OF FACTOR CONSUMPTION FOR ROUTINE PROPHYLAXIS AND BLEEDING DURING EPISODIC THERAPY WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN AND CONVENTIONAL RECOMBINANT FACTOR VIII
    Iorio, A.
    Krishnan, S.
    Myren, K.
    Lethagen, S.
    McCormick, N.
    Karner, P.
    VALUE IN HEALTH, 2015, 18 (07) : A660 - A660
  • [10] Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Real Life: One-Year Clinical and Economic Outcomes
    Romain Giraud
    Nicolas Delmotte
    Sophie Gensollen
    Martine Roche
    Céline Falaise
    Hervé Chambost
    Manon Roche
    Drugs - Real World Outcomes, 2021, 8 : 527 - 535
12345